GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » EV-to-FCF

Humacyte (Humacyte) EV-to-FCF : -9.49 (As of Jun. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Humacyte EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Humacyte's Enterprise Value is $792.62 Mil. Humacyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-83.53 Mil. Therefore, Humacyte's EV-to-FCF for today is -9.49.

The historical rank and industry rank for Humacyte's EV-to-FCF or its related term are showing as below:

HUMA' s EV-to-FCF Range Over the Past 10 Years
Min: -11.81   Med: 0   Max: 0
Current: -9.49

HUMA's EV-to-FCF is ranked worse than
100% of 377 companies
in the Biotechnology industry
Industry Median: 8.21 vs HUMA: -9.49

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-02), Humacyte's stock price is $7.47. Humacyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.000. Therefore, Humacyte's PE Ratio for today is At Loss.


Humacyte EV-to-FCF Historical Data

The historical data trend for Humacyte's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte EV-to-FCF Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -7.03 -1.61 -3.08

Humacyte Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.26 -2.53 -2.93 -3.08 -3.27

Competitive Comparison of Humacyte's EV-to-FCF

For the Biotechnology subindustry, Humacyte's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Humacyte's EV-to-FCF falls into.



Humacyte EV-to-FCF Calculation

Humacyte's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=792.623/-83.53
=-9.49

Humacyte's current Enterprise Value is $792.62 Mil.
Humacyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-83.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Humacyte  (NAS:HUMA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Humacyte's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.47/-1.000
=At Loss

Humacyte's share price for today is $7.47.
Humacyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Humacyte EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Humacyte's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte (Humacyte) Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente officer: Chief Regulatory Officer 90 DAVIS STREET, SEEKONK MA 02771
Todd Pope director C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713

Humacyte (Humacyte) Headlines

From GuruFocus